Regulatory worries, price erosion may pull down Dr Reddy's US revenues

Dr Reddy’s stock was down over 2 per cent on Wednesday after it received eight observations from the US drug regulator for its formulations manufacturing plant at Visakhapatnam. Analysts say this is a negative as the site was cleared by the regulator in February this year. While the company has indicated it will address the issues raised by the US Food and Drug Administration within the stipulated time frame, the new observations are a major concern.  Repeat observations for an approved facility are an indication of consistent regulatory challenges for the company, says an ana.....

Key stories on business-standard.com are available to premium subscribers only.

Already a premium subscriber?

Subscribe to get an across device (Website, Mobile Web, Iphone, Ipad, and Android Phone applications) access to Premium content, Breaking News alerts, Industry Newsletters, Stock and Corporate news alerts, access to Archives and a lot more.